105 results about "Transforming growth factor" patented technology

This invention belongs to the field of nutritional composition technology, specifically disclosing a composition for promoting brain cognitive development, its preparation method, and its application. The composition for promoting brain cognitive development provided by this invention includes transforming growth factor, casein phosphopeptide, immunoglobulin, and sn-2 DHA, and further specifies that the mass ratio of transforming growth factor, casein phosphopeptide, immunoglobulin, and sn-2 DHA is (0.1~1.4) ng:(40000~160000) mg:(20000~60000) mg:(20000~70000) mg. In this invention, the preferred ratio of transforming growth factor, casein phosphopeptide, immunoglobulin, and sn-2 DHA can achieve the effect of promoting brain cognitive development through a multi-dimensional synergistic mechanism.

The present invention addresses the problem of providing: synovium-derived mesenchymal stem cells that stably exhibit an excellent therapeutic effect on joint diseases; an arthropathy therapeutic agent that contains the synovium-derived mesenchymal stem cells; a method for producing the synovium-derived mesenchymal stem cells; and a method for selecting synovium-derived mesenchymal stem cells for use as an arthropathy therapeutic agent. The present invention provides synovium-derived mesenchymal stem cells that express at least one of a hepatocyte growth factor, a transforming growth factor β-inducing protein, and tumor necrosis factor superfamily 15.

The invention discloses a serum substitute compatible umbilical cord mesenchymal stem cell culture medium additive composition and application thereof. The serum substitute compatible umbilical cord mesenchymal stem cell culture medium additive composition is prepared from the following components in parts by mass: 15 to 25 parts of platelet-derived growth factor-BB; 15 to 25 parts of basic fibroblast growth factors; 8 to 12 parts of transforming growth factor-beta; and 8-12 parts of recombinant human insulin. The serum substitute compatible umbilical cord mesenchymal stem cell culture medium additive composition and the application thereof disclosed by the invention have the following beneficial effects: (1) the proliferation efficiency is remarkably improved; (2) the cell morphology and dryness can be well maintained; and (3) the compliance and the compatibility are good.

The invention relates to the technical field of biology, in particular to a human CD4 and TGF-beta1 / 2 / 3 combined bispecific antibody which at least comprises a first protein functional area, and the first protein functional area comprises a first antigen binding site targeting CD4; and the second protein functional region comprises a second antigen binding site targeting TGF (Transforming Growth Factor)-beta 1 / 2 / 3. The bispecific antibody disclosed by the invention can be well and specifically combined with CD4 and specifically combined to helper T cells; meanwhile, the bispecific antibody can be combined with TGF beta 1, so that Th1 cell mediated cellular immunity is activated, TGF beta 2 and TGF beta 3 are neutralized, and the bispecific antibody has the effect of preparing the medicine for preventing and treating bacterial infectious diseases.

This invention relates to a skin cell dispersion for autologous treatment of skin wounds. Specifically, this invention provides a skin cell dispersion containing skin cells, epidermal growth factor, and transforming growth factor-β1. The skin cell dispersion of this invention exhibits excellent therapeutic effects on skin wounds.

This invention provides an organ fibrosis-related micropeptide, OFMP, and its applications. This type of micropeptide, OFMP, is a translational product with endogenous biological activity and stable existence, encoded by an open reading frame (ORF) in a long non-coding RNA. It is the first time that the long non-coding RNA encoding the micropeptide has been found to be significantly related to organ fibrosis and can encode the micropeptide. Synthetic peptides prepared based on the aforementioned OFMP micropeptide show significant inhibitory effects on several key indicators of organ fibrosis, including type I collagen α1 chain gene, α-smooth muscle actin, transforming growth factor β1, and connective tissue growth factor. This indicates that the OFMP micropeptide, the nucleotide sequence (ORF) encoding the micropeptide, and the long non-coding RNA sequence containing the nucleotide sequence have important clinical diagnostic and therapeutic value for organ fibrosis.

The present disclosure provides methods for identifying therapeutic agents for treating ejection fraction preserved heart failure. The method may comprise: contacting a cardiac tissue or cardiac organoid with an effective amount of transforming growth factor-pi and an effective amount of endothelin-1 (ET-1) to induce ejection fraction preserved heart failure in the cardiac tissue; exposing the cardiac tissue or cardiac organoid exhibiting heart failure with preserved ejection fraction to a candidate therapeutic agent; and if the cardiac tissue or cardiac organoid induces a reduction in any one or more of the following characteristics of the cardiac tissue or cardiac organoid if the candidate therapeutic agent induces a reduction in any one or more of the following characteristics of the cardiac tissue or cardiac organoid, if yes, identifying the candidate therapeutic agent as a therapeutic agent for ejection fraction preserved heart failure: passive strain, stiffness, myocardial cell hypertrophy, or fibrosis. In some embodiments, the candidate therapeutic agent identified as a therapeutic agent for treating ejection fraction preserved heart failure induces an increase in contraction kinetics or relaxation kinetics. Additional embodiments of the disclosed methods identify therapeutic agents that induce any combination of the above altered characteristics of cardiac tissue and / or cardiac organoids.

The invention provides an induced pluripotent stem cell culture medium and a culture method of induced pluripotent stem cells. The induced pluripotent stem cell culture medium comprises a basic culture medium, a composite additive A and a composite additive B, the composite additive A comprises 5-30 [mu] g / mL of recombinant human insulin growth factors, 1-5 ng / mL of recombinant human transforming growth factors, 50-200 ng / mL of recombinant human basic fibroblast growth factors, 7-20 [mu] g / mL of sodium selenite, 0.5-2 mg / mL of albumin, 50-70 [mu] g / mL of ascorbic acid and 5-20 [mu] g / mL of transferrin; the composite additive B is prepared from 50 to 300mg / mL of a Stock B solution, 0.5 to 5 percent (v / v) of a non-essential amino acid solution, 50 to 200ng / mL of DL-piperidinecarboxylic acid, 50 to 200mu g / mL of gamma-aminobutyric acid, 0.1 to 1 percent (v / v) of a lipid concentrated solution, 0.5 to 5 percent (v / v) of an L-alanyl-L-glutamine solution and 0.1 to 0.1 percent of mercaptoethanol. The culture medium for the induced pluripotent stem cells provided by the invention can ensure the self-renewal capability of the iPSCs in a long-term passage process; and the genetic stability of the iPSCs cells is optimized according to the genome integrity and pluripotent state.

The invention discloses a method and a pharmaceutical composition for inhibiting tumor growth by combining an mRNA vaccine and a transforming growth factor-beta (TGF-beta) antibody. The medicine composition comprises an mRNA vaccine for coding a tumor specific antigen and a monoclonal antibody for specifically targeting TGF-beta, and tumor specific immune response induced by the mRNA vaccine is combined with the effect of the TGF-beta antibody for relieving tumor microenvironment immunosuppression, so that the killing ability of a body to tumor cells is remarkably enhanced; the compound provided by the invention can effectively inhibit tumor growth and prolong the lifetime of tumor-bearing individuals, has good safety and tolerance, and provides a new effective strategy for tumor treatment.

A treatment composition for inhibiting systemic sclerosis Vimentin mutant protein activity by using an STAT6 inhibitor, which inhibits the expression of an M2 macrophage and a profibrotic T cell which are immunocytes related to systemic sclerosis, and increases the expression of a Treg, and inhibits the expression of TGF-β, Col1a1, and α-SMA which are fibrosis factors related to systemic sclerosis. The presence of a pSTAT6 expression CD8 T cell in a fibrosis tissue has been identified, and that the expression of a pSTAT6 expression CD8 T positive cell is controlled via injection of the STAT6 inhibitor. In an animal model with increased Vimentin-specific disease symptom activity, the STAT6 inhibitor inhibits antigen-specific tissue fibrosis of systemic sclerosis with activated disease symptoms, and that the STAT6 inhibitor inhibits the expression of IL-17 cytokine expression CD8 positive TRM capable of inducing fibrosis and cell inflammation which are systemic sclerosis diseases.

The invention relates to the technical field of biological medicines, and particularly discloses an application composition of stem cell exosomes in promoting tissue repair, which comprises the stem cell exosomes selected from induced pluripotent stem cells, mesenchymal stem cells, embryonic stem cells, hematopoietic stem cells or neural stem cells and used for promoting tissue repair and cell regeneration, and the stem cell exosomes selected from the induced pluripotent stem cells, the mesenchymal stem cells, the embryonic stem cells, the hematopoietic stem cells and the neural stem cells. The tissue repair promoting factor is selected from an epidermal growth factor, a transforming growth factor beta, a platelet-derived growth factor or a combination thereof, and is used for optimizing cell proliferation, differentiation and wound healing; the biodegradable carrier is selected from hydrogel, lipidosome, polymer micelle, nano particles or natural plant extract; by optimizing the transmission relation between the biodegradable carrier and the stem cell exosome and combining with the cell proliferation model, different doses and delivery modes can be flexibly regulated and controlled, the treatment scheme is further optimized, and the effect of the treatment scheme is accurately predicted. Due to the design, the common problems of unstable effect, long treatment period and the like in the traditional stem cell application are solved.

The present disclosure provides nucleic acids encoding a transforming growth factor inhibitor and IL-12. Also provided herein are nucleic acids encoding the chemokine receptor CXCR3. Additionally described herein are oncolytic viruses comprising the nucleic acids described herein. The use of the compositions described herein in the treatment of cancer is also described.

The invention belongs to the technical field of tissue engineering, and particularly relates to a bio-ink system for osteochondral repair as well as a preparation method and application of the bio-ink system. The system comprises first bio-ink and second bio-ink which are respectively used for simulating cartilage and bone tissue. The first biological ink is prepared from methacrylic acid gelatin, acellular extracellular matrix powder, aldehyde modified natural polysaccharide, a photoinitiator and a transforming growth factor; the second biological ink is prepared from methacrylic acid gelatin, acellular extracellular matrix powder, nano-hydroxyapatite, aldehyde modified natural polysaccharide, a photoinitiator and human bone morphogenetic protein BMP-2. The bio-ink system can guarantee smooth extrusion and interlayer fusion in the printing process; the constructed bionic microenvironment and the affinity effect of the bionic microenvironment on growth factors are suitable for 3D printing construction of the osteochondral integrated bionic scaffold and have good clinical transformation potential.

The invention relates to the field of bone tissue engineering and regenerative medicine, in particular to non-denatured bone protein calcium superfine powder with bone tissue oriented growth and rapid repair effects and a preparation method and application of the non-denatured bone protein calcium superfine powder, and the non-denatured bone protein calcium superfine powder comprises the following components in percentage by weight: 25%-45% of non-denatured type I collagen, 0.005%-0.05% of bone morphogenetic protein-2, 0.001%-0.02% of transforming growth factor-beta1, 0.01%-0.02% of calcium sulfate, 0.01%-0.02% of calcium sulfate, 0.01%-0.02% of calcium The bone tissue repairing agent is prepared from, by weight, 0.001%-0.02% of basic fibroblast growth factors, 20%-40% of ultramicro hydroxyapatite nanoparticles, 5%-15% of chitosan oligosaccharide, 3%-10% of mannitol calcium complex, 2%-8% of sodium hyaluronate, 0.01%-0.1% of vitamin D3, 0.01%-0.1% of vitamin K2, 5%-15% of chondroitin sulfate, 1%-4% of casein phosphopeptides and the balance auxiliary materials, and directional growth and rapid repairing of bone tissue are promoted.

This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, long-term dialysis. For example, prediction of long-term dialysis treatment can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, a normalized time course of approximately fourteen Days measuring hyaluronic acid, death receptor 5, and / or transforming growth factor β1 can be used to establish the risk of recovery versus non-recovery in patient's having suffered an acute kidney injury.

This invention proposes a method for preparing dental pulp stem cell exosomes and their applications, belonging to the field of exosome technology. Dental pulp stem cells from exfoliated deciduous teeth are seeded into serum-free α-MEM medium containing microparticles, insulin-like growth factor, transforming growth factor-β1, penicillin, and streptomycin for culture. Exosomes are isolated, dispersed in PBS solution, and incubated with microparticles, propylene glycol, and rhodioloside to obtain highly active dental pulp stem cell exosomes. The surface of these exosomes is then modified with shikonin and interferon to obtain dental pulp stem cell exosomes. The dental pulp stem cell exosomes prepared by this invention exhibit good affinity for titanium implant-mediated osteointegration repair materials, demonstrating good anti-inflammatory, immunomodulatory, osteogenic, and damage-reducing effects. Furthermore, the preparation method is simple, yields high output, and operates under mild conditions, showing broad application prospects.

Compositions of matter and therapeutic methods for preventing, reducing, or reversing liver pathologies. Autologous pluripotent stem cells for generating monocytes or macrophages that are capable of suppressing liver failure. Methods of administering monocytes that are engineered or induced to facilitate hepatic regeneration. Hepatogenic cells such as monocytes are generated from induced pluripotent stem cells. Hepatogenic cells can be generated by overexpression of one or a plurality of factors associated with an M2 phenotype in pluripotent stem cell-derived monocytes such as signal transducer and activator of transcription 6 (STAT6) and transforming growth factor-beta. Hepatogenic monocytes can be generated in an environment that simulates liver injury.

This invention discloses the use of polylactic acid (PLA) and its copolymers in the preparation of products that promote hair follicle growth and repair, belonging to the field of biomedical technology. Through in vitro and in vivo experiments, this invention demonstrates that PLA can significantly upregulate the expression of lactate dehydrogenase A and transforming growth factor β2 in dermal papilla cells, promoting dermal papilla cell proliferation and hair follicle growth and damage repair. Based on these findings, this invention provides the application of PLA and its copolymers in the preparation of products that promote hair follicle growth and damage repair, offering a safe and effective treatment strategy for hair follicle-related diseases.

The present invention discloses a degradable tissue engineering labrum scaffold and a preparation method thereof. The scaffold uses a degradable polymer and an inorganic component as raw materials. Based on the melt electrostatic spinning process, the molten raw materials are stretched into fibers under the stretching effect of the electric field and the airflow field. The fibers are attached to a receiving roller to obtain highly oriented fiber bundles or fiber membranes. The fiber bundles or fiber membranes are loaded with polylactic-co-glycolic acid (PLGA) microspheres containing the small molecule drug bergenin and transforming growth factor β1 by spraying or soaking. The oriented fiber bundles or oriented fiber membranes after loading are curled to obtain oriented fiber aggregates. The obtained oriented fiber aggregates are placed in a pre-made mold for shaping, and the labrum scaffold is obtained after a period of time. The labrum scaffold prepared by the present invention has the advantages of bionic structure, solvent-free, high strength and good biocompatibility. It imitates the basic structure of the natural labrum composed of highly oriented circumferentially running collagen fiber bundles and has high tensile strength.

To provide a bifunctional protein capable of binding to PD-1 (programmed death receptor-1) and TGF-β (transforming growth factor-β), the medical use of the bifunctional protein, and a method for preparing the same.SOLUTION: A bifunctional protein comprises a PD-1 binding moiety and a TGF-β binding moiety, wherein the PD-1 binding moiety is preferably an anti-PD-1 antibody or an antigen-binding fragment thereof, for example, a full-length antibody, an Fab fragment, an F(ab')2 fragment, an Fv fragment, or a single chain Fv fragment (scFv).SELECTED DRAWING: Figure 1

The present invention relates to a composition for enhancing the activity of natural killer cells, and provides a composition for enhancing the activity of natural killer cells, the composition containing, as an active ingredient, a peptide having an amino acid sequence of SEQ ID NO: 1. The peptide having the amino acid sequence of SEQ ID NO: 1 according to the present invention not only increases the cytotoxicity of natural killer cells but also reduces the fratricide increased by TGF-β, and further improves the sensitivity of the natural killer cells to cancer cells. Thus, the peptide having the amino acid sequence of SEQ ID NO: 1 can be effectively used as an active ingredient for an anticancer drug or an anticancer adjuvant.

Provided are methods for evaluating therapeutic potency of extracellular vesicles (EVs) and methods for selecting a population of EVs for therapy by measuring amount of one or more of TGF-β1 (Transforming Growth Factor-β1), TSG-6 (Tumor Necrosis Factor-Stimulated Gene 6 protein), and let-7b-5p in the EVs. A method for treating a disease in a subject by measuring amount of one or more of TGF-β1, TSG-6, and let-7b-5p in EVs, isolating a portion of the EVs containing the one or more of TGF-β1, TSG-6, and let-7b-5p above a predetermined threshold, and administering a therapeutically effective amount of such EVs to the subject is also provided.

The invention belongs to the technical field of biological medicine, and particularly relates to a rheumatism immune disease treatment composition combining traditional Chinese medicine active ingredients and immune regulation and application of the rheumatism immune disease treatment composition, and the rheumatism immune disease treatment composition comprises the following components in parts by weight: 10-50 parts of a traditional Chinese medicine active ingredient compound; 0.01 to 1 part of an immune regulation factor; 50 to 90 parts of pharmaceutic adjuvants; wherein the traditional Chinese medicine active component compound is prepared from the following components: astragaloside, artemisinin, curcumin and triptolide in a weight ratio of (2-5): (1-3): (1-4): (0.5-2); the immunoregulation factor is composed of recombinant human interleukin-10 (rhIL-10), a transforming growth factor-beta1 (TGF-beta1) and a CTLA4-Ig fusion protein according to a weight ratio of (1-3): (0.5-2): (1-4). The active ingredients of the traditional Chinese medicine cover a plurality of links of anti-inflammation, anti-oxidation, immunoregulation and the like, and immunoregulatory factors accurately intervene in immune cell activation and a cell factor network to jointly inhibit abnormal immune response.

The invention provides a dental pulp stem cell exosome as well as a preparation method and application thereof, and belongs to the technical field of exosomes. The method comprises the following steps: inoculating exfoliated deciduous tooth pulp stem cells into a serum-free alpha-MEM culture medium containing microparticles, insulin-like growth factors, transforming growth factor-beta1, penicillin and streptomycin for culturing, separating exosomes, dispersing the exosomes into a PBS solution, adding microparticles, propylene glycol and salidroside for incubation, and separating to obtain the high-activity pulp stem cell exosomes. And performing surface modification on alkannic acid and interferon to prepare the dental pulp stem cell exosome. The dental pulp stem cell exosome prepared by the invention has relatively good affinity to a titanium implant material mediated osseointegration repair material, has relatively good advantages of resisting inflammation, regulating immunity, promoting osteogenesis, reducing injury and the like, is simple in preparation method, relatively high in yield and mild in condition, and has a wide application prospect.

The present invention relates to a compound of general formula (I) inhibiting the transforming growth factor-β (TGF-β) type I receptor (ALK5), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of ALK5 signaling pathway in a mammal.

The invention discloses a construction method of an in-vitro liver cancer liver invasion and metastasis experimental model, and relates to the technical field of model construction, and the construction method comprises the following steps: culturing liver cancer cells and hepatic stellate cells, carrying out fluorescence labeling, generating a space coordinate set by using the fluorescence labeled liver cancer cells and hepatic stellate cells, and calculating the in-vitro liver cancer liver invasion and metastasis experimental model. The method comprises the following steps of: printing liver cancer cells and hepatic stellate cells according to a space coordinate set to generate a three-dimensional cell-matrix structure, pouring photoresponse hydrogel into the three-dimensional cell-matrix structure, and inducing HOTAIR long non-coding RNA concentration by using a transforming growth factor to obtain the three-dimensional cell-matrix structure integrated with the photoresponse hydrogel. The space coordinate set is generated through the Markov model, accurate simulation of radial distribution of the highly invasive liver cancer cell core area and the hepatic stellate cells is achieved, and an accurate position template is provided for printing of a three-dimensional cell-matrix structure.

5 / 5-5 / 6 bisaryl compounds that inhibit transforming growth factor-β activated kinase (TAK1); compositions comprising the same; and their use for treating cancers and inflammatory diseases.

Described herein are biological devices and extracts useful for stimulating hair follicles and / or for increasing hair growth. The biological devices include microbial cells transformed with a DNA construct containing genes for producing transforming growth factor β, keratin, adiponectin, and thymosin β4. In some instances, the extracts also include a synthetic pentapeptide, GPIGS. Methods for using the devices and / or extracts to treat the scalp are also provided herein.

The present invention relates to compounds of formula (I) that inhibit transforming growth factor-beta (TGF-beta) type 1 receptor (ALK5), methods for preparing such compounds, pharmaceutical compositions containing them, and therapeutic uses thereof. The compounds of the present invention are useful for treating diseases or conditions in mammals associated with dysregulation of the ALK5 signaling pathway.

The invention discloses application of extracellular vesicle membrane protein in preparation of an early gastric cancer diagnostic kit. A series of novel EV membrane protein markers, namely transforming growth factor beta 1, annexin A2, tendon protein N, phospholipase-like structural domain protein 8, transferrin, fibroblast activation protein alpha and cadherin 5, are jointly screened by using a proteomics technology and an EVArray platform. Clinical verification proves that the application potential of the gene in early diagnosis and postoperative monitoring of GC gastric cancer. Wherein the transforming growth factor beta 1 and the tendon protein N have the most significant value in GC early diagnosis.